BMJ14d
Vascular occlusion for optimising the functional improvement in patients with knee osteoarthritis: a randomised controlled trial
Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
BMJ3d
Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs
Correspondence to Dr Jörg H W Distler, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, ...
BMJ5d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ3d
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
Objective Immune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) ...
BMJ11d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ13d
Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis
Correspondence to Dr Ki-Jo Kim, Division of Rheumatology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, ...
BMJ8d
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Objectives To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
BMJ14d
Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE
Objectives The goals of these studies were to elucidate the inter-relationships of specific anti-nuclear antibody (ANA), complement, and the interferon gene signature (IGS) in the pathogenesis of ...
BMJ10d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ14d
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive ...
BMJ13d
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Objective To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods Fifty-three patients with active disease from an ongoing ...
BMJ13d
Mortality and causes of death in a Swedish series of systemic sclerosis patients
OBJECTIVES To analyse survival rates and the causes of death in a systemic sclerosis (SSc) population, and to evaluate the occurrence of fatal malignant neoplasms and their possible association with ...